Kiniksa Pharmaceuticals International, plc Overview
Pro stress-test →Kiniksa Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. The company achieved full-year profitability in 2025 propelled by exceptional commercial performance of its flagship drug, ARCALYST. ARCALYST generated 2025 net product revenue of $677.5 million, representing ~62% year-over-year growth.
Strategic Profile
Pro stress-test →IL-1α & IL-1β inhibition with ARCALYST is increasingly becoming the preferred second line treatment for patients with recurrent pericarditis, with approximately 18% of the multiple recurrence population actively on ARCALYST therapy as of end-2025. The company has disciplined focus of R&D resources on its next-generation IL-1 inhibitor pipeline (KPL-387 and KPL-1161), following discontinuation of other clinical programs.
Competitive Landscape
Pro stress-test →Kiniksa competes in the biopharmaceutical space focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Primary competitors include other cardiovascular specialty pharma companies and immunology-focused biotech firms pursuing IL-1 pathway interventions.
Industry Context
Kiniksa Pharmaceuticals International, plc operates in Biopharmaceuticals - Specialty & Immunology.
Key facts
Founded: 2015 · Headquarters: London, UK · Revenue: $678M · Market cap: $3.24B